SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced the online availability of an updated Investor Fact Sheet highlighting the Company’s strategic vision for continued growth by developing and commercializing cutting-edge drugs focused on innovative methods of modulating the human immune system.
